Abstract
We compared the efficacy and safety of a new fixed combination of timolol 0.5%/odorzolamide 20%/brimonidine 0.2% in ophthalmic solution versus a fixed combination of timolol 0.5%/dorzolamide 2% in patients with open-angle glaucoma or ocular hypertension. The fixed triple combination was significantly more efficient in mean intraocular pressure reduction from baseline throughout the six-month follow-up.
Publication types
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenergic alpha-Agonists / administration & dosage
-
Antihypertensive Agents / administration & dosage
-
Brimonidine Tartrate
-
Carbonic Anhydrase Inhibitors / administration & dosage
-
Dose-Response Relationship, Drug
-
Drug Combinations
-
Female
-
Follow-Up Studies
-
Glaucoma, Open-Angle / drug therapy*
-
Glaucoma, Open-Angle / physiopathology
-
Humans
-
Intraocular Pressure / drug effects*
-
Male
-
Middle Aged
-
Ocular Hypertension / drug therapy
-
Ocular Hypertension / physiopathology
-
Ophthalmic Solutions
-
Prospective Studies
-
Quinoxalines / administration & dosage*
-
Sulfonamides / administration & dosage*
-
Thiophenes / administration & dosage*
-
Time Factors
-
Timolol / administration & dosage*
-
Treatment Outcome
Substances
-
Adrenergic alpha-Agonists
-
Antihypertensive Agents
-
Carbonic Anhydrase Inhibitors
-
Drug Combinations
-
Ophthalmic Solutions
-
Quinoxalines
-
Sulfonamides
-
Thiophenes
-
Brimonidine Tartrate
-
Timolol
-
dorzolamide